Cancer treatment reviews最新文献_第7页

Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis 曲妥珠单抗德鲁西替康治疗人表皮生长因子受体2阳性乳腺癌脑转移：一项系统综述和最新荟萃分析

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-02-01 DOI: 10.1016/j.ctrv.2025.102882

Isabella Michelon , Caio E.R. Castro , Thiago Madeira , Maria Inez Dacoregio , Carlos Stecca , Leonardo R. Soares , Anwaar Saeed , Maysa Vilbert , Ludimila Cavalcante

{"title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis","authors":"Isabella Michelon , Caio E.R. Castro , Thiago Madeira , Maria Inez Dacoregio , Carlos Stecca , Leonardo R. Soares , Anwaar Saeed , Maysa Vilbert , Ludimila Cavalcante","doi":"10.1016/j.ctrv.2025.102882","DOIUrl":"10.1016/j.ctrv.2025.102882","url":null,"abstract":"<div><h3>Background</h3><div>Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated <em>meta</em>-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.</div></div><div><h3>Methods</h3><div>A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD). We used random effects models for all statistical analyses.</div></div><div><h3>Results</h3><div>We included 18 studies with 786 HER2-positive BC patients with CNS involvement (16 studies with 750 BMs patients and three studies with 36 LMD patients). We observed high overall antitumor responses (objective response rate [ORR], 60.4 %; disease control rate [DCR], 94.4 %; and clinical benefit rate [CBR], 79.3 %) and a 12-month PFS of 64.7 % and OS of 82.7 %. Intracranial ORR, DCR, and CBR were seen in 62.2 %, 88.6 %, and 68.6 % of patients, respectively, and 67.4 % achieved intracranial PFS at 12 months. Both stable and active BMs subgroups derived similar benefit from T-DXd. Better intracranial responses were seen for 33 patients with untreated BMs compared to 56 patients with previously treated or progressing lesions (odds ratio 3.82, 95 % confidence interval 1.3–10.8, p = 0.01). For the LMD group, T-DXd elicited intracranial ORR and CBR in 59.4 % and 94.1 % of patients, respectively.</div></div><div><h3>Conclusions</h3><div>This updated <em>meta</em>-analysis continues to support the overall and intracranial activity of T-DXd in patients with HER2-positive BC and CNS involvement, including those with LMD.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"133 ","pages":"Article 102882"},"PeriodicalIF":9.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dendritic cells in triple-negative breast cancer: From pathophysiology to therapeutic applications 树突状细胞在三阴性乳腺癌中的作用：从病理生理学到治疗应用。

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-02-01 DOI: 10.1016/j.ctrv.2025.102884

Ana Isabel Sebastião , Gonçalo Simões , Filomena Oliveira , Daniela Mateus , Amílcar Falcão , Mylène A. Carrascal , Célia Gomes , Bruno Neves , Maria Teresa Cruz

{"title":"Dendritic cells in triple-negative breast cancer: From pathophysiology to therapeutic applications","authors":"Ana Isabel Sebastião , Gonçalo Simões , Filomena Oliveira , Daniela Mateus , Amílcar Falcão , Mylène A. Carrascal , Célia Gomes , Bruno Neves , Maria Teresa Cruz","doi":"10.1016/j.ctrv.2025.102884","DOIUrl":"10.1016/j.ctrv.2025.102884","url":null,"abstract":"<div><div>Breast cancer is the second most commonly diagnosed cancer in women and the fifth leading cause of cancer-related deaths worldwide. It is a highly heterogeneous disease, consisting of multiple subtypes that vary significantly in clinical characteristics and survival outcomes. Triple-negative breast cancer (TNBC) is a particularly aggressive and challenging subtype of breast cancer. Several immunotherapeutic approaches have been tested in patients with TNBC to improve disease outcomes, including the administration of dendritic cell (DC)-based vaccines. DCs are a heterogeneous cell population that play a crucial role in bridging the innate and adaptive immune systems. Therefore, DCs have been increasingly used in cancer vaccines due to their ability to prime and boost antigen specific T-cell immune responses. This review aims to provide a comprehensive overview of TNBC, including potential targets and pharmacological strategies, as well as an overview of DCs and their relevance in TNBC. In addition, we review ongoing clinical trials and shed light on the evolving landscape of DC-based immunotherapy for TNBC.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"133 ","pages":"Article 102884"},"PeriodicalIF":9.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications 选择全身治疗转移性肺神经内分泌肿瘤-目前的证据和临床意义。

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-02-01 DOI: 10.1016/j.ctrv.2024.102878

Philipp Melhorn, Markus Raderer, Barbara Kiesewetter

{"title":"Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications","authors":"Philipp Melhorn, Markus Raderer, Barbara Kiesewetter","doi":"10.1016/j.ctrv.2024.102878","DOIUrl":"10.1016/j.ctrv.2024.102878","url":null,"abstract":"<div><div>Neuroendocrine tumors (NET) of the lung are a slowly growing subtype of lung cancer that has a different treatment paradigm than aggressive and more common forms of lung neuroendocrine neoplasms (NEN) like small cell lung cancer (SCLC). Current guidelines for metastatic lung NET advocate a handful of treatment options, including somatostatin analogs (SSA), everolimus, temozolomide- or platin-based chemotherapy, and peptide receptor radionuclide therapy (PRRT). However, there is no clear treatment sequence, and the therapy of choice may depend on several factors such as tumor grade / growth rate, tumor burden / symptoms, disease progression status, and somatostatin receptor (SSTR) expression. In order to tailor treatment to each individual patient, the latest scientific findings and patient-specific clinical features must be considered together. This review critically evaluates the available evidence with regards to relevant patient characteristics, inclusion and exclusion criteria, and outcome metrics of clinical trials given the presumed natural disease course. Specific patient subgroups with an unmet therapeutic need are identified and discussed in the context of ongoing clinical trials.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"133 ","pages":"Article 102878"},"PeriodicalIF":9.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 晚期肾细胞癌患者对免疫疗法和 TKI 抗药性的动态变化。

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-02-01 DOI: 10.1016/j.ctrv.2025.102881

Matteo Santoni , Veronica Mollica , Alessandro Rizzo , Francesco Massari

{"title":"Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma","authors":"Matteo Santoni , Veronica Mollica , Alessandro Rizzo , Francesco Massari","doi":"10.1016/j.ctrv.2025.102881","DOIUrl":"10.1016/j.ctrv.2025.102881","url":null,"abstract":"<div><div>Immune-based combinations are the cornerstone of the first-line treatment of metastatic renal cell carcinoma patients, leading to outstanding outcomes. Nevertheless, primary resistance and disease progression is a critical clinical challenge. To properly address this issue, it is pivotal to understand the mechanisms of resistance to immunotherapy and tyrosine kinase inhibitors, that tumor eventually develop under treatment.</div><div>In this review of the literature, we aim at exploring resistance mechanisms arising in patients treated with first-line immune-based combinations in order to understand the biological pattern that should be investigated to overcome them.</div><div>In more detail, mechanisms of resistance to nivolumab and pembrolizumab are divided into intrinsic to cancer cells and extrinsic (stromal or immune cells). Regarding axitinib, the increased expression of Nuclear protein 1 (NUPR1) or decreased levels of insulin receptor (INSR) characterize resistant cells. The secretion of non-VEGF pro-angiogenic factors, such as PDGF-BB, IL-1β, MMP-9, Gro-α, IL-8, IL-6, and CCL-2, can lead to resistance to cabozantinib. The reactivation of pathways previously targeted by lenvatinib or the activation of alternative pathways, such as EGFR-PAK2-ERK pathway, underlie the development of resistance to lenvatinib.</div><div>Exploring resistance mechanism that arise during first-line therapy can lead to the development of treatment strategy able to overcome them in order to improve duration of response and patients outcomes.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"133 ","pages":"Article 102881"},"PeriodicalIF":9.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy 黑色素瘤相关抗原 A4：作为采用 T 细胞受体 T 细胞疗法靶点的癌症/睾丸抗原

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-01-26 DOI: 10.1016/j.ctrv.2025.102891

Gabrielle Knafler , Alan L. Ho , Kathleen N. Moore , Seth M. Pollack , Jean-Marc Navenot , Joseph P. Sanderson

{"title":"Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy","authors":"Gabrielle Knafler , Alan L. Ho , Kathleen N. Moore , Seth M. Pollack , Jean-Marc Navenot , Joseph P. Sanderson","doi":"10.1016/j.ctrv.2025.102891","DOIUrl":"10.1016/j.ctrv.2025.102891","url":null,"abstract":"<div><div>T-cell receptor (TCR) T-cell therapies are adoptive cell therapies in which patient cells are engineered to express TCRs targeting specific cancer antigens and infused back into the patient. Since TCR recognition depends on antigen presentation by the human leukocyte antigen system, TCRs can respond to intracellular antigens. Cancer/testis antigens (CTAs) are a large family of proteins, many of which are only expressed in cancerous tissue and immune-privileged germline sites. Melanoma-associated antigen A4 (MAGE-A4) is an intracellular CTA expressed in healthy testis and placenta, and in a range of cancers, including esophageal, head and neck, gastric, ovarian, colorectal, lung, endometrial, cervical, bladder, breast and prostate cancers; soft tissue sarcomas; urothelial and hepatocellular carcinomas; osteosarcoma; and melanoma. This expression pattern, along with the immunogenicity and potential role in tumorigenesis of MAGE-A4 make it a prime target for TCR T-cell therapy. We outline the preclinical and clinical development of TCR T-cell therapies targeting CTAs for treatment of solid tumors, highlighting the need for extensive preclinical characterization of putative off-target, and potential on-target but off-tumor, effects. We identified ten clinical trials assessing TCR T-cell therapies targeting MAGE-A4. Overall, manageable safety profiles and signals of efficacy have been observed, especially in patients with advanced synovial sarcoma, myxoid/round cell liposarcoma, ovarian, head and neck, and urothelial cancers, with one TCR T-cell therapy approved by the US Food and Drug Administration in August 2024. We also review the limitations, and strategies to enhance efficacy and improve safety, of these therapies, and summarize related immunotherapies targeting MAGE-A4.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"134 ","pages":"Article 102891"},"PeriodicalIF":9.6,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143436695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis and management of bispecific T cell–engaging antibody toxicity: A primer for emergency physicians 双特异性T细胞参与抗体毒性的诊断和管理：急救医生的入门读物

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-01-24 DOI: 10.1016/j.ctrv.2025.102889

Monica K Wattana , Jonathan Rowland , Aiham Qdaisat , Hannah Levavi , Theodora Anagnostou , Larysa Sanchez , Philip Friedlander , Nicholas Rohs , Demis N. Lipe , Joshua Richter

{"title":"Diagnosis and management of bispecific T cell–engaging antibody toxicity: A primer for emergency physicians","authors":"Monica K Wattana , Jonathan Rowland , Aiham Qdaisat , Hannah Levavi , Theodora Anagnostou , Larysa Sanchez , Philip Friedlander , Nicholas Rohs , Demis N. Lipe , Joshua Richter","doi":"10.1016/j.ctrv.2025.102889","DOIUrl":"10.1016/j.ctrv.2025.102889","url":null,"abstract":"<div><h3>Background</h3><div>T-cell-engaging bispecific antibodies (BsAbs) are a newer type of immunotherapy designed to boost T-cell cytotoxicity. They are increasingly used in cancer treatment, with drugs currently being tested and authorized for treating both liquid and solid tumors. It’s becoming more likely that emergency physicians and other acute care practitioners will treat patients experiencing adverse events related to bispecific antibodies, as these drugs are regularly given in the outpatient setting. Currently, BsAb-associated side effects are not routinely taught to Emergency Medicine residents, and a paucity of literature exists to guide currently practicing Emergency Medicine physicians and other acute care practitioners about these medications.</div></div><div><h3>Objective of the review</h3><div>This review was written by emergency medicine physicians in collaboration with oncologists who routinely administer BsAbs to provide guidelines and an overview on diagnosis, treatment, and management strategies for adverse events related to bispecific antibodies.</div></div><div><h3>Discussion</h3><div>Side effects related to BsAbs require a multidisciplinary treatment approach ideally with oncologists notified early when an adverse event is suspected. Symptom presentation is subtle with BsAb toxicity and the main adverse events to consider working up are cytokine release syndrome, immune effector cell neurotoxicity, and infection. The article also discusses unique side effects specific to FDA-approved drugs to treat leukemia, multiple myeloma, lymphoma, lung cancer, and melanoma given that this drug class has heterogeneous receptor-specific side effects.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"134 ","pages":"Article 102889"},"PeriodicalIF":9.6,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143223576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current controversies in the use of Oncotype DX in early breast cancer Oncotype DX治疗早期乳腺癌的争议

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-01-16 DOI: 10.1016/j.ctrv.2025.102887

Pier Paolo M. Berton Giachetti , Ambra Carnevale Schianca , Dario Trapani , Antonio Marra , Angela Toss , Caterina Marchiò , Maria Vittoria Dieci , Oreste Davide Gentilini , Carmen Criscitiello , Kevin Kalinsky , Joseph A. Sparano , Giuseppe Curigliano

{"title":"Current controversies in the use of Oncotype DX in early breast cancer","authors":"Pier Paolo M. Berton Giachetti , Ambra Carnevale Schianca , Dario Trapani , Antonio Marra , Angela Toss , Caterina Marchiò , Maria Vittoria Dieci , Oreste Davide Gentilini , Carmen Criscitiello , Kevin Kalinsky , Joseph A. Sparano , Giuseppe Curigliano","doi":"10.1016/j.ctrv.2025.102887","DOIUrl":"10.1016/j.ctrv.2025.102887","url":null,"abstract":"<div><div>Multigene prognostic genomic assays have become essential tools in the management of early breast cancer (BC), providing information that help in risk-stratification, to provide risk-adapted decision-making of adjuvant treatments. Clinical practice guidelines recommend refining the prognostic information provided by clinical and pathology features with the use of genomic tests, such as Oncotype DX®, to classify cancers into risk groups and inform adjuvant treatment strategies. However, the clinical value (i.e., prognostic and/or predictive) and applicability of these assays vary due to differences in the clinical setting, especially in those populations that were underrepresented in pivotal clinical trials. Oncotype DX® is a broadly utilized genomic test for breast cancer, having the highest level of supporting evidence to inform clinical practice. Our manuscript provides a comprehensive overview on this recurrence score assay, evaluates supporting evidence across patient populations, and discusses their impact on treatment decisions in those groups of patients underrepresented in pivotal clinical trials, where evidence is limited with the use of Oncotype DX.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102887"},"PeriodicalIF":9.6,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives” [Cancer Treat. Rev. 131 (2024) 102850] 《神经胶质瘤中的PARP抑制剂：作用机制、当前趋势和未来展望》[癌症治疗]的更正。Rev. 131(2024) 102850]。

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-01-01 DOI: 10.1016/j.ctrv.2024.102866

Eugenia Cella , Alberto Bosio , Pasquale Persico , Mario Caccese , Marta Padovan , Agnese Losurdo , Marta Maccari , Giulia Cerretti , Tamara Ius , Giuseppe Minniti , Ahmed Idbaih , Nader Sanai , Michael Weller , Matthias Preusser , Matteo Simonelli , Giuseppe Lombardi

引用次数: 0

Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review 胃肠胰神经内分泌癌一线铂类化疗后的维持治疗：文献综述。

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-01-01 DOI: 10.1016/j.ctrv.2024.102863

Natalia Soledad Tissera , Francesca Balconi , Alejandro García-Álvarez , Jorge Hernando Cubero , Juan Manuel O'Connor , Matías Chacón , Jaume Capdevila

引用次数: 0

Current status and future prospects of combined immunotherapy and epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma 头颈部鳞状细胞癌的免疫疗法与表皮生长因子受体抑制剂联合疗法的现状与前景。

IF 9.6 1区医学

Cancer treatment reviews Pub Date : 2025-01-01 DOI: 10.1016/j.ctrv.2024.102864

Xin Tian , Hongyan Zhang , Yiman Han , Baoru Gu , Zhenyong Zhang

{"title":"Current status and future prospects of combined immunotherapy and epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma","authors":"Xin Tian , Hongyan Zhang , Yiman Han , Baoru Gu , Zhenyong Zhang","doi":"10.1016/j.ctrv.2024.102864","DOIUrl":"10.1016/j.ctrv.2024.102864","url":null,"abstract":"<div><div>Head and neck squamous cell carcinoma (HNSCC) is a malignancy with a poor prognosis, and the majority of patients with HNSCC are diagnosed at later stages owing to its hidden anatomical location and atypical clinical symptoms. It is notably prone to recurrence and metastasis. The traditional treatments include surgery, radiotherapy, chemotherapy, and targeted therapy. Although multiple treatment strategies have been established, the prognosis remains poor because most patients develop resistance to traditional treatments. In recent years, epidermal growth factor receptor (EGFR) inhibitors and immune checkpoint inhibitors (ICIs) have been shown to provide clinical benefits to these patients. Based on the promising results of both anti-EGFR therapy and immunotherapy, as well as the biological rationale for combining immunotherapy with anti-EGFR drugs, numerous preclinical and ongoing or completed clinical trials have explored the use of their synergistic effects. This review summarizes the feasibility of combining immunotherapy with EGFR inhibitors for HNSCC treatment and analyses the relevant biomarkers. It also summarizes the strategies for clinical applications. We found that immunotherapy and EGFR inhibitor combination therapy showed promise in treating patients with HNSCC and exhibited safety with acceptable adverse events. This review may provide valuable insights for the future development of treatments and formulation of therapeutic strategies for HNSCC, as well as useful information for the future design of clinical trials.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"132 ","pages":"Article 102864"},"PeriodicalIF":9.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0